Home Cart Sign in  
Chemical Structure| 915385-81-8 Chemical Structure| 915385-81-8

Structure of ABC294640
CAS No.: 915385-81-8

Chemical Structure| 915385-81-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ABC294640 markedly alters the ratio of ceramide/S1P consistent with inhibition of SK activity in MDA-MB-231 cells.

Synonyms: Opaganib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ABC294640

CAS No. :915385-81-8
Formula : C23H25ClN2O
M.W : 380.91
SMILES Code : O=C(C12CC3(C4=CC=C(Cl)C=C4)CC(C2)CC(C3)C1)NCC5=CC=NC=C5
Synonyms :
Opaganib
MDL No. :MFCD22666355
InChI Key :CAOTVXGYTWCKQE-UHFFFAOYSA-N
Pubchem ID :15604015

Safety of ABC294640

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 cells 50 µM 24 hours To test the effect of SPHK2 inhibitor on human monocytes and to evaluate inflammatory cytokine levels. Cell Death Discov. 2023 Jan 18;9(1):12.
NSCLC cell-lines (A549, H460, H1299) 20 µM 48 hours ABC294640 treatment caused significant G2 phase arrest and induced apoptosis in NSCLC cells. Int J Cancer. 2018 May 15;142(10):2153-2162.
PC cell lines 15 mM 6 hours To investigate the effect of SPHK inhibitors on ENZ resistance in cell line models. EBioMedicine. 2021 Oct;72:103625.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice ALI model induced by LPS Intraperitoneal injection 20 mg/kg Once after LPS administration To alleviate macrophage-evoked oxidative injury and inflammatory reaction in lung tissues. Cell Death Discov. 2023 Jan 18;9(1):12.
Mice H460 xenograft model Intraperitoneal injection 75 mg/kg 3 days/week for 3 weeks ABC294640 treatment represses tumor growth in vivo. Int J Cancer. 2018 May 15;142(10):2153-2162.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04502069 COVID-19|Lung Infection PHASE1|PHASE2 WITHDRAWN 2025-06-21 Shaare Zedek Medical Center, J... More >>erusalem, Israel Less <<
NCT02229981 Diffuse Large B Cell Lymphoma|... More >>Kaposi Sarcoma Less << PHASE1|PHASE2 WITHDRAWN 2025-12-19 Louisiana State University Hea... More >>lth Sciences Center, New Orleans, Louisiana, 70112, United States Less <<
NCT02757326 Multiple Myeloma PHASE1|PHASE2 TERMINATED 2025-05-19 Duke University Medical Center... More >>, Durham, North Carolina, 27705, United States Less <<
NCT02939807 Carcinoma, Hepatocellular PHASE2 WITHDRAWN 2024-01-30 Medical University of South Ca... More >>rolina, Charleston, South Carolina, 29425, United States Less <<
NCT03414489 Cholangiocarcinoma|Cholangioca... More >>rcinoma Non-resectable|Cholangiocarcinoma, Perihilar|Cholangiocarcinoma, Extrahepatic|Cholangiocarcinoma, Intrahepatic Less << AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.13mL

2.63mL

1.31mL

26.25mL

5.25mL

2.63mL

References

 

Historical Records

Categories